A global perspective in second-line treatment patterns for patients with advanced esophageal squamous cell carcinoma.

ABSTRACT:

Background

Esophageal cancer is a highly prevalent cancer associated with low survival, especially among those with advanced disease. Second-line (2L) treatment patterns and related clinical outcomes of patients with advanced esophageal squamous cell carcinoma (advESCC) treated in routine clinical care were examined globally and regionally.

Methods

A retrospective, noninterventional study collected physician-provided chart data of patients aged ≥20 years receiving either 2L active systemic therapy or BSC following first-line active therapy for advESCC from 11 countries in Asian and Western regions (September-October 2018). Bivariate analyses examined treatment and outcomes by region.

Results

AdvESCC patients (Asia = 192; West = 195) were examined, of which 58.1% (Asia

SUBMITTER: Jaffe DH 

PROVIDER: S-EPMC9058306 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature